Cellectis S.A. (CLLS) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001627281

P/B 4.22

P/E -12.00

P/S 5.14

Market Cap 424.24 Mn

ROIC (Qtr) -12.26

Div Yield % 0.00

Rev 1y % (Qtr) 105.89

Total Debt (Qtr) 119.22 Mn

Debt/Equity (Qtr) 1.19

About

Cellectis S.A., known by its ticker symbol CLLS, operates in the biotechnological industry with a focus on gene-editing technologies. The company's core business activities involve the development of allogeneic Chimeric Antigen Receptor T-cells (CAR T-cells) for immuno-oncology applications and gene-edited hematopoietic stem and progenitor cells (HSPC) for other therapeutic indications. Cellectis utilizes its proprietary technologies to produce cost-effective, "off-the-shelf" products that can be distributed worldwide. Cellectis operates in the...

Cellectis S.A., known by its ticker symbol CLLS, operates in the biotechnological industry with a focus on gene-editing technologies. The company's core business activities involve the development of allogeneic Chimeric Antigen Receptor T-cells (CAR T-cells) for immuno-oncology applications and gene-edited hematopoietic stem and progenitor cells (HSPC) for other therapeutic indications. Cellectis utilizes its proprietary technologies to produce cost-effective, "off-the-shelf" products that can be distributed worldwide.

Cellectis operates in the rapidly evolving field of gene-editing, where it has established a strong competitive position. The company's unique gene-editing technology, coupled with its portfolio of proprietary product candidates, sets it apart from its competitors. Cellectis' gene-edited CAR T-cell product candidates are designed to harness the power of the immune system to target and eradicate cancer cells. The company's primary products include UCART19, ALLO-501, ALLO-316, and ALLO-715, among others. These products are designed to target specific antigens, such as CD19, BCMA, and CD70, to treat various cancers and diseases.

Cellectis generates revenue through licensing agreements with major pharmaceutical companies, including AstraZeneca, Allogene, and Servier. Under these agreements, the company grants exclusive rights to develop and commercialize its gene-edited CAR T-cell product candidates for specific indications. These partnerships demonstrate the confidence that major players in the industry have in Cellectis' technology and product pipeline.

In terms of clinical development, Cellectis has a number of ongoing clinical trials. These include a Phase 1 clinical trial of UCART19 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). The company is also conducting a Phase 1 clinical trial of ALLO-501 in patients with relapsed or refractory multiple myeloma (MM). Additionally, Cellectis is conducting a Phase 1 clinical trial of ALLO-316 in patients with relapsed or refractory renal cell carcinoma (RCC).

Cellectis' TALEN gene editing platform enables the efficient and precise editing of genes, which is critical for the development of highly specific and effective gene-edited CAR T-cell product candidates. The company has also entered into a number of collaborations and agreements with other companies, including a research collaboration and exclusive license agreement with Iovance Biotherapeutics and a research collaboration and non-exclusive license agreement with Cytovia Therapeutics.

Stock Price Chart

Analysis

Pros

Strong tangible asset base of 342.20M provides 2.87x coverage of total debt 119.22M, indicating robust asset backing and low credit risk.
Short-term investments of 139.98M provide solid 1.32x coverage of other current liabilities 105.91M, indicating strong liquidity.
Operating cash flow of (29.09M) provides strong 31.93x coverage of operating expenses (911000), showing operational efficiency.
Robust tangible asset base of 342.20M provides 4.71x coverage of working capital 72.62M, indicating strong operational backing.
R&D investment of 89.95M represents healthy 0.96x of deferred revenue 94.01M, indicating strong future innovation pipeline.

Cons

Operating cash flow of (29.09M) barely covers its investment activities of (68.60M), with a coverage ratio of 0.42, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of (68.60M) provide weak support for R&D spending of 89.95M, which is -0.76x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Operating cash flow of (29.09M) provides insufficient coverage of deferred revenue obligations of 94.01M, which is -0.31x, raising concerns about future service delivery capabilities.
The company's operating cash flow of (29.09M) shows concerning coverage of stock compensation expenses of 4.74M, with a -6.13 ratio indicating potential earnings quality issues.
Free cash flow of (31.52M) provides weak coverage of capital expenditures of 2.43M, with a -12.97 ratio suggesting additional external financing needs for growth initiatives.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	1.39	12.31
EV to Cash from Ops.	-16.44	23.25
EV to Debt	4.01	738.44
EV to EBIT	-54.61	-9.16
EV to EBITDA	-85.16	6.95
EV to Free Cash Flow [EV/FCF]	-15.17	21.90
EV to Market Cap	1.13	65.67
EV to Revenue	5.79	227.32
Price to Book Value [P/B]	4.22	22.34
Price to Earnings [P/E]	-12.00	-11.77

Dividend Metrics

Metric	Value	Industry
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	-0.34	841.00

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	-5.28	-27.13
Cash and Equivalents Growth (1y) %	-67.16	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	79.39	-46.93
EBITDA Growth (1y) %	90.52	-1.68
EBIT Growth (1y) %	79.81	-56.45
EBT Growth (1y) %	59.01	-12.70
EPS Growth (1y) %	66.67	-28.31
FCF Growth (1y) %	-152.15	-31.90
Gross Profit Growth (1y) %	133.83	226.84

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.24	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	0.35	3.85
Current Ratio	1.49	7.27
Debt to Equity Ratio	1.19	0.40
Interest Cover Ratio	-0.34	841.00
Times Interest Earned	-0.34	841.00

Profitability

Metric	Value	Industry
EBITDA Margin %	14.60	-18,234.31
EBIT Margin %	-10.61	-18,580.80
EBT Margin %	-42.20	-19,488.74
Gross Margin %	100.00	-7.59
Net Profit Margin %	-42.80	-19,439.22

Cellectis S.A. (NASDAQ: CLLS)